novartis-pharma
Novartis Wins US Approval for Targeted Cancer Drug Combination

Novartis Wins US Approval for Targeted Cancer Drug Combination

A targeted oral drug combination by Novartis won US approval for use in a wide range.

Novartis Wins US Approval for Targeted Cancer Drug Combination
IHSG
7.172,43
0.20%
-14,12
LQ45
1.022,99
0.33%
-3,35
USD/IDR
14.822
0,37
EMAS
974.000
0,10%